DE29709313U1 - Preparation for muscle maintenance or to promote muscle building - Google Patents
Preparation for muscle maintenance or to promote muscle buildingInfo
- Publication number
- DE29709313U1 DE29709313U1 DE29709313U DE29709313U DE29709313U1 DE 29709313 U1 DE29709313 U1 DE 29709313U1 DE 29709313 U DE29709313 U DE 29709313U DE 29709313 U DE29709313 U DE 29709313U DE 29709313 U1 DE29709313 U1 DE 29709313U1
- Authority
- DE
- Germany
- Prior art keywords
- hydroxy
- acid
- amino acid
- muscle
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000003205 muscle Anatomy 0.000 title claims description 18
- 238000002360 preparation method Methods 0.000 title claims description 12
- 238000012423 maintenance Methods 0.000 title claims description 8
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims description 46
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 229960003136 leucine Drugs 0.000 claims description 22
- 239000004395 L-leucine Substances 0.000 claims description 21
- 235000019454 L-leucine Nutrition 0.000 claims description 21
- 229940024606 amino acid Drugs 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 21
- NPOAOTPXWNWTSH-UHFFFAOYSA-N 3-hydroxy-3-methylglutaric acid Chemical compound OC(=O)CC(O)(C)CC(O)=O NPOAOTPXWNWTSH-UHFFFAOYSA-N 0.000 claims description 13
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 239000003531 protein hydrolysate Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 230000037257 muscle growth Effects 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 description 23
- 150000005693 branched-chain amino acids Chemical class 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 230000001195 anabolic effect Effects 0.000 description 6
- 230000003160 anti-catabolic effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000007792 addition Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 150000008544 L-leucines Chemical class 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000576 supplementary effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
Patentanwälte ·. .. ,..,Patent attorneys · .. ,..,
\2'].: »I··..\.: .·* 5597/28.5.97 \2'].: »I··..\.: .·* 5597/28.5.97
European Patent Attorneys *··**··* *.·*·..European Patent Attorneys *··**··* *.·*·..
Die Erfindung betrifft ein Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus. The invention relates to a preparation for maintaining muscle or promoting muscle growth.
Aue Eiweiße des menschlichen Körpers unterliegen einem ständigen Auf- und Abbau. Beim normalen, gesunden jungen Erwachsenen halten sich Eiweißaufbau und Eiweißabbau weitgehend die Waage, daher bleibt der Bestand an Körpereiweiß erhalten. Ist der Eiweißaufbau geringer als der Eiweißabbau, so befindet sich der Mensch in einer Eiweißkatabolie. Diese Situation tritt bei hohen körperlichen Belastungen, bei Nährstoffmangel, aber auch mit zunehmendem Alter oder bei bestimmten Erkrankungen, auf. Wenn der Eiweißaufbau gegenüber dem Eiweißabbau überwiegt, so befindet sich der Mensch in einer Eiweißanabolie. Dies ist der Zustand, den der Kraftsportler anstrebt und neben diesem auch der sich von einer schweren Krankheit erholende Mensch und natürlich Kinder und Heranwachsende.All proteins in the human body are constantly being built up and broken down. In normal, healthy young adults, protein buildup and protein breakdown are largely balanced, so the body's protein levels are maintained. If protein buildup is less than protein breakdown, the person is in a state of protein catabolism. This situation occurs with high physical exertion, with nutrient deficiencies, but also with increasing age or with certain illnesses. If protein buildup outweighs protein breakdown, the person is in a state of protein anabolicism. This is the state that strength athletes strive for, as well as people recovering from a serious illness and, of course, children and adolescents.
Der biologische Abbau- und Alterungsprozeß setzt beim Menschen bereits in der Lebensmitte ein. Unter anderem nimmt die Muskelmasse ab dem 35. bis 40. Lebensjahr jedes Jahr um etwa 1 % ab, was mit einem Rückgang der körperlichen Leistungsfähigkeit verbunden ist.The biological degradation and aging process begins in humans in midlife. Among other things, muscle mass decreases by around 1% every year from the age of 35 to 40, which is associated with a decline in physical performance.
Daraus ergibt sich, daß, um die Muskeln aufzubauen oder im Alter zu erhalten, entweder die anabolen Prozesse maximiert oder die katabolen Prozesse minimiert werden müssen oder noch besser, daß beides gleichzeitig eintritt. Man weiß heute, daß, wenn es darum geht, eine Gesamtkörpereiweißanabolie zu erzielen, das Minimieren von Abbauprozessen wesentlich effektiver ist als eine Maximierung der Aufbauprozesse.This means that in order to build muscle or maintain it as you age, either the anabolic processes must be maximized or the catabolic processes minimized, or even better, both must occur at the same time. We now know that when it comes to achieving total body protein anabolicity, minimizing breakdown processes is much more effective than maximizing building processes.
Um diesen Eiweißanabolie-Zustand zu erreichen, können Zusatzsubstanzen verwendet werden. Kraftsportlern sind zahlreiche solcher Substanzen bekannt.Additional substances can be used to achieve this protein anabolic state. Strength athletes are familiar with numerous such substances.
Dazu gehören die verzweigtkettigen Aminosäuren, die sogenannten BCAAs (branched chain amino acids), die vom Körper als Baumaterial für Muskelgewebe benötigt werden und damit eine anabole Funktion haben. Diese Aminosäuren werden primär beim Training zur Energiegewinnung verstoffwechselt bzw. verbraucht. Unter diesen Aminosäuren spielt L-Leucin eine besondere Rolle. Die Einnahme von BCAAs vor dem Training wirkt in erster LinieThese include the branched chain amino acids, the so-called BCAAs (branched chain amino acids), which are needed by the body as building material for muscle tissue and thus have an anabolic function. These amino acids are primarily metabolized or consumed during training to generate energy. Among these amino acids, L-leucine plays a special role. Taking BCAAs before training primarily has an
Patentanwälte Viel & VielPatent Attorneys Viel & Viel
European Patent AttorneysEuropean Patent Attorneys
5597/28.5.975597/28.5.97
antikatabol, da die supplementierten Aminosäuren und nicht vorhandenes Körperprotein "verbrannt" werden.anti-catabolic, because the supplemented amino acids and non-existent body protein are "burned".
Alpha-Keto-isocaproat (KIC) ist ein Abkömmling der Aminosäure L-Leucin, d.h. es wird im Körper aus L-Leucin gebildet. KIC hat ähnlich gute Eigenschaften wie L-Leucin, ist aber viel teurer. Viele wissenschaftliche Studien beweisen, daß sowohl L-Leucin als auch KIC, wenn sie über den täglichen Mindestbedarf hinaus zugeführt werden, den Muskelabbau reduzieren und die Proteinsynthese steigern, also nicht nur antikatabole, sondern echte anabole Effekte haben. Eine aufgenommene Menge von etwa 15 bis 60 g L-Leucin pro Tag wird benötigt, um die Trainingsverluste an L-Leucin auszugleichen und die normalen Aufbauprozesse, die durch Training stimuliert werden, überhaupt zu ermöglichen. Diese Menge an L-Leucin ist sozusagen die Grundvoraussetzung dafür, daß Muskelaufbau überhaupt stattfinden kann.Alpha-keto-isocaproate (KIC) is a derivative of the amino acid L-leucine, i.e. it is formed in the body from L-leucine. KIC has similar properties to L-leucine, but is much more expensive. Many scientific studies prove that both L-leucine and KIC, when taken in excess of the daily minimum requirement, reduce muscle breakdown and increase protein synthesis, thus having not only anti-catabolic but real anabolic effects. An intake of around 15 to 60 g of L-leucine per day is required to compensate for the training losses of L-leucine and to enable the normal building processes that are stimulated by training. This amount of L-leucine is, so to speak, the basic prerequisite for muscle building to take place at all.
BCAAs und KIC haben zwei Hauptnachteile. Einerseits kann die tägliche Zufuhrmenge an BCAAs und L-Leucin nicht beliebig erhöht werden, denn es ist bekannt, daß übermäßig hohe Zufuhrmengen von L-Leucin zu einer unerwünschten Aminosäureimbalanz des Körpers führt, welche die antikatabolen L-Leucinvorteile aufhebt und sogar negiert. Andererseits sind ziemlich große Mengen erforderlich, um das gewünschte Ziel zu erreichen. Es wird meistens empfohlen, 15 bis 60 g BCAAs mit 40 %igem L-Leucinanteil vor dem Training zusätzlich zu einer hochwertigen Ernährung mit hohen Proteinanteil zu sich zu nehmen.BCAAs and KIC have two main disadvantages. On the one hand, the daily intake of BCAAs and L-leucine cannot be increased indefinitely, because it is known that excessively high intake of L-leucine leads to an undesirable amino acid imbalance in the body, which cancels out and even negates the anti-catabolic benefits of L-leucine. On the other hand, fairly large amounts are required to achieve the desired goal. It is usually recommended to take 15 to 60 g of BCAAs with 40% L-leucine before training in addition to a high-quality, high-protein diet.
Die Erfindung hat zur Aufgabe, ein Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus zu schaffen, das gegenüber bekannten Präparaten eine bessere Muskelerhaltung bzw. eine Steigerung des Muskelaufbaus mit sich bringt.The invention aims to create a preparation for muscle maintenance or for promoting muscle building, which brings about better muscle maintenance or an increase in muscle building compared to known preparations.
Diese Aufgabe wird erfindungsgemäß durch ein Präparat zur Muskelerhaltung bzw. zur
Förderung des Muskelaufbaus gelöst, das eine Mischung von
ß-Hydroxy-ß-methylbuttersäure (HM-Beta) oder Salzen davon und
ß-Hydroxy-ß-methylglutarsäure oder Salzen davon
enthält.This task is achieved according to the invention by a preparation for muscle maintenance or
Promoting muscle building, which is a mixture of
ß-Hydroxy-ß-methylbutyric acid (HM-Beta) or salts thereof and
ß-Hydroxy-ß-methylglutaric acid or salts thereof
contains.
Eine Weiterbildung der Erfindung besteht darin, daß die Mischung mindestens eine
Aminosäure, ein Protein, ein Proteinhydrolysat oder ein Derivat einer Aminosäure allein oder
in Form von Mischungen enthält.A further development of the invention consists in that the mixture contains at least one
Amino acid, a protein, a protein hydrolysate or a derivative of an amino acid alone or
in the form of mixtures.
Es liegt im Rahmen der Erfindung, daß der Anteil von ß-Hydroxy-ß-methylbuttersäure (HM-Beta)
und von ß-Hydroxy-ß-methylglutarsäure an der Mischung jeweils mindestens 5
Gewichts-% beträgt.It is within the scope of the invention that the proportion of ß-hydroxy-ß-methylbutyric acid (HM-Beta)
and ß-hydroxy-ß-methylglutaric acid in the mixture at least 5
% by weight.
Patentanwälte ViELi& VielPatent Attorneys ViELi& Viel
European Patent AttorneysEuropean Patent Attorneys
5597/28.5.975597/28.5.97
Erfindungsgemäß ist vorgesehen, daß die Aminosäure L-Leucin ist.According to the invention, the amino acid is L-leucine.
Weiterhin ist es vorteilhaft, daß das Derivat der Aminosäure a-Keto-isocaproat (KIC) ist.Furthermore, it is advantageous that the derivative of the amino acid is a-keto-isocaproate (KIC).
Die Vorteile der Erfindung bestehen im wesentlichen darin, daß überraschenderweise die
Kombination aus einer Aminosäure und einem Abbauprodukt einer Aminosäure sowie einem
Produkt, das aus dem Abbauprodukt metabolisiert wird, zu einem signifikant besseren
Muskelerhalt bzw. -aufbau fuhrt als die Einnahme allein der Aminosäure. Ein weiterer Vorteil
der Erfindung liegt darin, daß die obengenannte notwendige Aufhahmemenge an Proteinen,
Proteinhydrolysat, BCAAs, oder deren Derivaten reduziert werden kann und dennoch gleiche
oder sogar bessere Effekte erzielt werden können. Ein anwendungstechnischer Vorteil liegt in
der Tatsache, daß anstelle von zwei Präparaten nur eines eingenommen werden muß.The advantages of the invention are essentially that, surprisingly, the
Combination of an amino acid and a degradation product of an amino acid and a
Product that is metabolized from the degradation product to a significantly better
Muscle maintenance or building than taking the amino acid alone. Another advantage
The invention is that the above-mentioned necessary intake of proteins,
Protein hydrolysate, BCAAs, or their derivatives can be reduced and still the same
or even better effects can be achieved. An application-related advantage lies in
the fact that only one preparation needs to be taken instead of two.
Es wird vermutet, daß nicht die BCCAs oder der L-Leucinabkömmling KIC den antikatabolen Effekt hervorrufen, sondern das Folgeprodukt ß-Hydroxy-ß-methylbuttersäure, das aus diesen Substanzen gebildet wird. Dieses ß-Hydroxy-ß-methylbuttersäure (HM-Beta) ist eine kurzkettige Fettsäure, die im Körper aus der Nahrungsaminosäure L-Leucin gebildet wird. In dem Leucin-Stoffwechsel wird ß-Hydroxy-ß-methylbuttersäure (HM-Beta) weiter zu ß-Hydroxy-ß-methylglutarsäure abgebaut. Es wird davon ausgegangen, daß ß-Hydroxy-ßmethylglutarsäure wie ein Co-Faktor zu ß-Hydroxy-ß-methylbuttersäure (HM-Beta) wirkt, da die Zugabe dieser Substanz aufgrund von Verschiebungen des chemischen Gleichgewichts den Abbau von ß-Hydroxy-ß-methylbuttersäure (HM-Beta) abpuffert, also verlangsamt. Hieraus ergibt sich eine synergistische Wirkung beider Substanzen, deren Wirkung verstärkt und zeitlich verlängert wird.It is assumed that it is not the BCCAs or the L-leucine derivative KIC that cause the anti-catabolic effect, but the secondary product ß-hydroxy-ß-methylbutyric acid, which is formed from these substances. This ß-hydroxy-ß-methylbutyric acid (HM-Beta) is a short-chain fatty acid that is formed in the body from the dietary amino acid L-leucine. In the leucine metabolism, ß-hydroxy-ß-methylbutyric acid (HM-Beta) is further broken down into ß-hydroxy-ß-methylglutaric acid. It is assumed that ß-hydroxy-ß-methylglutaric acid acts like a co-factor to ß-hydroxy-ß-methylbutyric acid (HM-Beta), since the addition of this substance buffers, i.e. slows down, the breakdown of ß-hydroxy-ß-methylbutyric acid (HM-Beta) due to shifts in the chemical equilibrium. This results in a synergistic effect of both substances, the effect of which is enhanced and prolonged.
Bei durchschnittlicher Ernährung werden im Körper etwa 3 g, bei proteinreicher Sportlerernährung etwa 5 g ß-Hydroxy-ß-methylbuttersäure (HM-Beta) pro Tag synthetisiert. ß-Hydroxy-ß-methylbuttersäure (HM-Beta) ist ein Nährstoff, der im Eiweißaufbau- bzw. Eiweißerhaltungsstoffwechsel eine wichtige ernährungsphysiologische Rolle spielt. Wie es für solche Derivate typisch ist, wird auch ß-Hydroxy-ß-methylbuttersäure (HM-Beta) nur in kleinen Mengen im menschlichen Körper gefunden, denn der Körper hat kaum Speichermöglichkeiten für ß-Hydroxy-ß-methylbuttersäure (HM-Beta). Offensichtlich haben zusätzlich durch die Nahrung aufgenommene etwa 1,5 g dieses Derivats, wenn es bei gedecktem L-Leucinbedarf zugeführt wird, sehr gute anabole bzw. antikatabole Eigenschaften, die nicht, auch mit zusätzlichen sehr hohen L-Leucin- oder KIC-Einnahmemengen, erreicht werden können. Bei der erfindungsgemäßen Mischung von ß-Hydroxy-ß-methylbuttersäureWith an average diet, the body synthesizes around 3 g of ß-hydroxy-ß-methylbutyric acid (HM-Beta) per day, and with a protein-rich sports diet, around 5 g. ß-hydroxy-ß-methylbutyric acid (HM-Beta) is a nutrient that plays an important nutritional role in protein synthesis and protein maintenance metabolism. As is typical for such derivatives, ß-hydroxy-ß-methylbutyric acid (HM-Beta) is only found in small amounts in the human body, because the body has hardly any storage capacity for ß-hydroxy-ß-methylbutyric acid (HM-Beta). Obviously, an additional 1.5 g of this derivative taken in through food, when taken when L-leucine requirements are met, has very good anabolic or anti-catabolic properties that cannot be achieved even with additional very high L-leucine or KIC intake. In the inventive mixture of ß-hydroxy-ß-methylbutyric acid
Patentanwälte Viel & VielPatent Attorneys Viel & Viel
European Patent AttorneysEuropean Patent Attorneys
5597/28.5.975597/28.5.97
(HM-Beta) und ß-Hydroxy-ß-methylglutarsäure ist aufgrund der oben dargelegten synergistischen Wirkung die anabole bzw. antikatabole Wirkung noch deutlich besser.(HM-Beta) and ß-hydroxy-ß-methylglutaric acid, the anabolic or anti-catabolic effect is significantly better due to the synergistic effect described above.
Jedoch können Zugaben von ß-Hydroxy-ß-methylbuttersäure (HM-Beta) und ß-Hydroxy-ßmethylglutarsäure das Zufuhr von L-Leucin nicht ersetzen, da L-Leucin eine lebensnotwendige Aminosäure ist, die von dem Körper nicht gebildet werden kann, außer durch Abbau von anderen Körperproteinen.However, additions of ß-hydroxy-ß-methylbutyric acid (HM-Beta) and ß-hydroxy-ß-methylglutaric acid cannot replace the intake of L-leucine, since L-leucine is an essential amino acid that cannot be produced by the body except by breaking down other body proteins.
Die Kombination von BCAAs, insbesondere von L-Leucin, mit ß-Hydroxy-ß-methylbuttersäure (HM-Beta) und ß-Hydroxy-ß-methylglutarsäure scheint überraschenderweise den L-Leucinbedarf zu senken. Erste Untersuchungen zeigen, daß sich die ernährungsphysiologischen Effekte der Proteine bzw. Aminosäuren sowie von ß-Hydroxy-ßmethylbuttersäure (HM-Beta) und ß-Hydroxy-ß-methylglutarsäure nicht nur addieren, sondern offensichtlich sogar in gewissem Maße potenzieren, also synergistisch verstärken, wobei dies von der Aminosäurezusammensetzung des mit ß-Hydroxy-ß-methylbuttersäure (HM-Beta) und ß-Hydroxy-ß-methylglutarsäure kombinierten Produktes abhängig zu sein scheint. Erste Studien deuten bei der Kombination von bestimmten Proteinhydrolysaten und/oder Aminosäure-mischungen mit ß-Hydroxy-ß-methylbuttersäure (HM-Beta) und ß-Hydroxy-ßmethylglutarsäure auf noch bessere Ergänzungswirkungen als bei reinen Proteinen hin.The combination of BCAAs, especially L-leucine, with ß-hydroxy-ß-methylbutyric acid (HM-Beta) and ß-hydroxy-ß-methylglutaric acid surprisingly appears to reduce the L-leucine requirement. Initial studies show that the nutritional effects of the proteins and amino acids as well as of ß-hydroxy-ß-methylbutyric acid (HM-Beta) and ß-hydroxy-ß-methylglutaric acid not only add up, but also evidently potentiate to a certain extent, i.e. synergistically strengthen, whereby this appears to depend on the amino acid composition of the product combined with ß-hydroxy-ß-methylbutyric acid (HM-Beta) and ß-hydroxy-ß-methylglutaric acid. Initial studies indicate that the combination of certain protein hydrolysates and/or amino acid mixtures with ß-hydroxy-ß-methylbutyric acid (HM-Beta) and ß-hydroxy-ß-methylglutaric acid has even better supplementary effects than pure proteins.
So konnten bei einer Supplementierung von 1,5 g ß-Hydroxy-ß-methylbuttersäure (HM-Beta) pro Tag mit einer Eiweißmast von 200 g pro Tag schon ähnliche Ergebnisse erzielt werden, wie mit einer Eiweißmast von 400 g pro Tag ohne Zugabe von ß-Hydroxy-ß-methylbuttersäure (HM-Beta). Bemerkenswert ist, daß bereits ein 0,25 %iger ß-Hydroxy-ß-methylbuttersäure (HM-Beta)-Zusatz ein Nahrungsprotein bzw. eine Aminosäure enorm aufwertet und die Proteineffizienz signifikant anhebt. Es hat sich gezeigt, daß mit der Kombination von ß-Hydroxy-ß-methylbuttersäure (HM-Beta) und ß-Hydroxy-ß-methylglutarsäure noch signifikant bessere Wirkungen erzielbar sind.Thus, with a supplementation of 1.5 g of ß-hydroxy-ß-methylbutyric acid (HM-Beta) per day with a protein feed of 200 g per day, similar results could be achieved as with a protein feed of 400 g per day without the addition of ß-hydroxy-ß-methylbutyric acid (HM-Beta). It is noteworthy that even a 0.25% ß-hydroxy-ß-methylbutyric acid (HM-Beta) supplement enormously improves the value of a dietary protein or an amino acid and significantly increases protein efficiency. It has been shown that even significantly better effects can be achieved with the combination of ß-hydroxy-ß-methylbutyric acid (HM-Beta) and ß-hydroxy-ß-methylglutaric acid.
Claims (5)
ß-Hydroxy-ß-methylbuttersäure (HM-Beta) oder Salzen davon und ß-Hydroxy-ß-methylglutarsäure oder Salzen davon enthält.1. Preparation for muscle maintenance or for promoting muscle growth, characterized in that it contains a mixture of
Contains ß-hydroxy-ß-methylbutyric acid (HM-Beta) or salts thereof and ß-hydroxy-ß-methylglutaric acid or salts thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE29709313U DE29709313U1 (en) | 1997-04-23 | 1997-05-28 | Preparation for muscle maintenance or to promote muscle building |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE29707308U DE29707308U1 (en) | 1997-04-23 | 1997-04-23 | Preparation for muscle maintenance or to promote muscle building |
| DE29709313U DE29709313U1 (en) | 1997-04-23 | 1997-05-28 | Preparation for muscle maintenance or to promote muscle building |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE29709313U1 true DE29709313U1 (en) | 1997-09-11 |
Family
ID=8039401
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE29707308U Expired - Lifetime DE29707308U1 (en) | 1997-04-23 | 1997-04-23 | Preparation for muscle maintenance or to promote muscle building |
| DE29709313U Expired - Lifetime DE29709313U1 (en) | 1997-04-23 | 1997-05-28 | Preparation for muscle maintenance or to promote muscle building |
| DE29709574U Expired - Lifetime DE29709574U1 (en) | 1997-04-23 | 1997-05-28 | Preparation for muscle maintenance or to promote muscle building |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE29707308U Expired - Lifetime DE29707308U1 (en) | 1997-04-23 | 1997-04-23 | Preparation for muscle maintenance or to promote muscle building |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE29709574U Expired - Lifetime DE29709574U1 (en) | 1997-04-23 | 1997-05-28 | Preparation for muscle maintenance or to promote muscle building |
Country Status (1)
| Country | Link |
|---|---|
| DE (3) | DE29707308U1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999066917A3 (en) * | 1998-06-23 | 2000-04-20 | Univ Iowa State Res Found Inc | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid |
| WO2004056208A1 (en) * | 2002-12-20 | 2004-07-08 | Nutricia N.V. | Stimulation of in vivo production of proteins with formulation comprising leucine |
| WO2011094544A1 (en) * | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Nutritional emulsions comprising calcium hmb and soluble protein |
| US8217077B2 (en) | 2004-03-26 | 2012-07-10 | Abbott Laboratories | HMB uses thereof |
| US8916217B2 (en) | 2010-01-29 | 2014-12-23 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising HMB |
| US9241508B2 (en) | 2010-01-29 | 2016-01-26 | Abbott Laboratories | Nutritional emulsions comprising calcium HMB |
| US9521859B2 (en) | 2010-06-10 | 2016-12-20 | Normanella T. Dewille | Substantially clear nutritional liquids comprising calcium HMB and soluble protein |
| US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5227182B2 (en) | 2005-12-19 | 2013-07-03 | アボット・ラボラトリーズ | Use of beta-hydroxy-beta-methylbutyrate to regulate imbalances in type 1 and type 2 cytokine production |
-
1997
- 1997-04-23 DE DE29707308U patent/DE29707308U1/en not_active Expired - Lifetime
- 1997-05-28 DE DE29709313U patent/DE29709313U1/en not_active Expired - Lifetime
- 1997-05-28 DE DE29709574U patent/DE29709574U1/en not_active Expired - Lifetime
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU756353B2 (en) * | 1998-06-23 | 2003-01-09 | Iowa State University Research Foundation Inc. | Composition comprising beta-hydroxy-beta-methylbutyric acid and at least one amino acid and methods of use |
| WO1999066917A3 (en) * | 1998-06-23 | 2000-04-20 | Univ Iowa State Res Found Inc | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid |
| WO2004056208A1 (en) * | 2002-12-20 | 2004-07-08 | Nutricia N.V. | Stimulation of in vivo production of proteins with formulation comprising leucine |
| US7288570B2 (en) | 2002-12-20 | 2007-10-30 | Nutricia N.V. | Stimulation of in vivo production of proteins |
| US8785495B2 (en) | 2004-03-26 | 2014-07-22 | Abbott Laboratories | Compositions including beta-hydroxy-beta-methylbutyrate |
| US8217077B2 (en) | 2004-03-26 | 2012-07-10 | Abbott Laboratories | HMB uses thereof |
| US8609725B2 (en) | 2004-03-26 | 2013-12-17 | Abbott Laboratories | Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate |
| US8778994B2 (en) | 2004-03-26 | 2014-07-15 | Abbott Laboratories | Method of using beta-hydroxy-beta-methylbutyrate and fatty acids for treating disease-associated wasting |
| US8778993B2 (en) | 2004-03-26 | 2014-07-15 | Abbott Laboratories | Method of using β-hydroxy-β-methylbutyrate for the treatment of disease conditions |
| US8785496B2 (en) | 2004-03-26 | 2014-07-22 | Abbott Laboratories | Method of using beta-hydroxy-beta-methylbutyrate for treating disease-associated wasting |
| WO2011094544A1 (en) * | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Nutritional emulsions comprising calcium hmb and soluble protein |
| EP2792251A1 (en) * | 2010-01-29 | 2014-10-22 | Abbott Laboratories | Nutritional emulsions comprising calcium HMB and soluble protein |
| US8916217B2 (en) | 2010-01-29 | 2014-12-23 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising HMB |
| US9241508B2 (en) | 2010-01-29 | 2016-01-26 | Abbott Laboratories | Nutritional emulsions comprising calcium HMB |
| US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
| US9521859B2 (en) | 2010-06-10 | 2016-12-20 | Normanella T. Dewille | Substantially clear nutritional liquids comprising calcium HMB and soluble protein |
Also Published As
| Publication number | Publication date |
|---|---|
| DE29709574U1 (en) | 1997-08-28 |
| DE29707308U1 (en) | 1997-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60024593T2 (en) | Pharmaceutical, dietetic cosmetic compositions containing thioctic acid and cysteine | |
| DE60207877T2 (en) | Composition containing procyanidins for reducing appetite in mammals | |
| DE60034898T2 (en) | Antiallergic composition containing OLIGOSACCHARIDs and a saponin or basic amino acid for topical administration or inhalation | |
| DE29709313U1 (en) | Preparation for muscle maintenance or to promote muscle building | |
| EP1137341B1 (en) | Baby food stimulating growth of the thymus | |
| EP0826370B1 (en) | Pharmaceutical composition comprising 2-phenyl-1,2-benzoisoelenazol-3(2H)-one for the treatment of Alzheimer disease | |
| WO1990011023A1 (en) | Additive for food and fodder | |
| DE1667887B1 (en) | Aminosaeurelösungen for parenteral infusion | |
| DE212019000123U1 (en) | Hematococcus pluvialis powder composition with an antioxidant effect | |
| DE2853194A1 (en) | Foodstuff based on soya protein - produced by treating with honey, useful as dietetic and therapeutic foodstuff | |
| DE4119170C2 (en) | Remedies for atopic dermatitis | |
| DE60209793T2 (en) | MODIFIED METHIONOLOGICAL NUTRITION AND METHOD FOR THE PRODUCTION THEREOF | |
| EP0717632B1 (en) | A food additive for improving immunity | |
| DE60206545T2 (en) | Composition for drinking / eating containing AGARICUS BLAZEI MURRILL | |
| AT410277B (en) | DRINK | |
| EP0265662A2 (en) | Pharmaceutic composition | |
| DE60122701T2 (en) | COSMETIC OR DERMATOLOGICAL CREAM PREPARATION, THEIR PREPARATION AND USE | |
| DE60020888T2 (en) | EXTRACTS FROM HERBS FOR THE TREATMENT OF COGNITIVE DISTURBANCES DUE TO ESTROGEN LOSS | |
| DE102006036887B4 (en) | Composition for a means of care, growth promotion and strengthening of skin, hair and nails and its use | |
| DE19922932B4 (en) | Cosmetic preparation and process for its preparation | |
| EP0384308A1 (en) | Extract medicament | |
| DE202015102041U1 (en) | Oral composition containing collagen hydrolyzate and vitamin C. | |
| DE19910697C2 (en) | Process for the preparation of a therapeutically active substance and use thereof | |
| CH704360B1 (en) | Additive, useful in e.g. skin cream, comprises e.g. composition comprising DNA from wheat germ, extract from connective tissues of tuna fish, composition comprising active ingredients from yeast, hyaluronic acid solution and water | |
| EP4199943A1 (en) | Composition comprising manuka honey and phycobiliprotein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R207 | Utility model specification |
Effective date: 19971023 |
|
| R150 | Utility model maintained after payment of first maintenance fee after three years |
Effective date: 20000626 |
|
| R157 | Lapse of ip right after 6 years |
Effective date: 20031202 |